Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia

References

• Feng L, Ng XT, Yap P, et al. Marital status and cognitive impairment among Community-Dwelling Chinese older adults: the role of gender and social engagement. Dement Geriatr Cogn Dis Extra. 2014;4(3):375–384.
   PubMedGoogle Scholar
• Reas ET, Laughlin GA, Bergstrom J, et al. Effects of sex and education on cognitive change over a 27-Year period in older adults: the rancho bernardo study. Am J Geriatr Psychiatry. 2017;25(8):889–899.
   PubMed Web of Science ®Google Scholar
• Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63(10):1902–1907.
   PubMed Web of Science ®Google Scholar
• Klemp JR, Myers JS, Fabian CJ, et al. Cognitive functioning and quality of life following chemotherapy in pre- and peri-menopausal women with breast cancer. Support Care Cancer. 2018;26(2):575–583.
   PubMed Web of Science ®Google Scholar
• Correa DD, Hess LM. Cognitive function and quality of life in ovarian cancer. Gynecol Oncol. 2012;124(3):404–409.
   PubMed Web of Science ®Google Scholar
• Williams AM, Lindholm J, Cook D, et al. Association between cognitive function and quality of life in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2017;143(12):1228–1235.
   PubMed Web of Science ®Google Scholar
• Aiki S, Okuyama T, Sugano K, et al. Cognitive dysfunction among newly diagnosed older patients with hematological malignancy: frequency, clinical indicators and predictors. Jpn J Clin Oncol. 2018;48(1):61–67.
   PubMed Web of Science ®Google Scholar
• Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;133(34):4085–4092.
   PubMed Web of Science ®Google Scholar
• Williams AM, van Wijngaarden E, Seplaki CL, et al. Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. Leuk Lymphoma. 2020;61(7):1627–1635.
   PubMed Web of Science ®Google Scholar
• Nakamura ZM, Deal AM, Rosenstein DL, et al. Cognitive function in patients prior to undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2021;29(4):2007–2014.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hendrix CC. Cancer-Related cognitive impairment in breast cancer patients: Influences of psychological variables. Asia Pac J Oncol Nurs. 2018;5(3):296–306.
   PubMed Web of Science ®Google Scholar
• Anderson DE, Kedar S, Bhatt VR, et al. Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: a feasibility study. J Neurol Sci. 2020;410:116644.
   PubMed Web of Science ®Google Scholar
• Sharafeldin N, Bosworth A, Patel SK, et al. Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: Results from a prospective longitudinal study. J Clin Oncol. 2018;36(5):463–475.
   PubMed Web of Science ®Google Scholar
• Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology. 2009;18(8):811–821. Aug
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64(2):165–176.
   PubMed Web of Science ®Google Scholar
• Joly F, Heutte N, Duclos B, et al. Prospective evaluation of the impact of antiangiogenic treatment on cognitive functions in metastatic renal cancer. Eur Urol Focus. 2016;2(6):642–649.
   PubMedGoogle Scholar
• Mulder SF, Bertens D, Desar IM, et al. Impairment of cognitive functioning during sunitinib or sorafenib treatment in cancer patients: a cross sectional study. BMC Cancer. 2014;14:219.
   PubMed Web of Science ®Google Scholar
• Scheibel RS, Valentine AD, O'Brien S, et al. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci. 2004;16(2):185–191.
   PubMed Web of Science ®Google Scholar
• Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857. Aug 20
   PubMed Web of Science ®Google Scholar
• Saglio G, Gale RP. Prospects for achieving treatment-free remission in chronic myeloid leukaemia. Br J Haematol. 2020;190(3):318–327.
   PubMed Web of Science ®Google Scholar
• Meadows ME, Chang G, Jones JA, et al. Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome. Arch Clin Neuropsychol. 2013;28(4):363–374. Jun
   PubMed Web of Science ®Google Scholar
• Chang G, Meadows ME, Smallwood JA, et al. Cognitive and other predictors of change in quality of life one year after treatment for chronic myelogenous leukemia or myelodysplastic syndrome. J Neuropsychiatry Clin Neurosci. 2014;26(3):249–257.
   PubMed Web of Science ®Google Scholar
• Aziz Z, Iqbal J, Aaqib M, et al. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leukemia & Lymphoma. 2011;52(6):1017–1023.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884.
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789–799.
   PubMed Web of Science ®Google Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686–692.
   PubMed Web of Science ®Google Scholar
• Qin YZ, Jiang Q, Jiang H, et al. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(is) or log reduction from the baseline level? Leuk Res. 2013;37(9):1035–1040.
   PubMed Web of Science ®Google Scholar
• Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;12(6):371–379.
   PubMed Web of Science ®Google Scholar
• Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63–70.
   PubMed Web of Science ®Google Scholar
• Leung KK, Lue BH, Lee MB, et al. Screening of depression in patients with chronic medical diseases in a primary care setting. Fam Pract. 1998;15(1):67–75.
   PubMed Web of Science ®Google Scholar
• Liu XC, Oda S, Peng X, et al. Life events and anxiety in Chinese medical students. Soc Psychiatry Psychiatr Epidemiol. 1997;32(2):63–67. Feb
   PubMed Web of Science ®Google Scholar
• Li H, Jin D, Qiao F, et al. Relationship between the Self-Rating anxiety scale score and the success rate of 64-slice computed tomography coronary angiography. Int J Psychiatry Med. 2016;51(1):47–55.
   PubMed Web of Science ®Google Scholar
• Hao T, Youxiang M, Xiuyong D, et al. [Prevalence and psychopathological characteristics of anxiety and depression in patients with chronic rhinosinusitis before endoscopic sinus surgery]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;50(3):210–214.
   PubMedGoogle Scholar
• Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.
   PubMed Web of Science ®Google Scholar
• Arcuri GG, Palladini L, Dumas G, et al. Exploring the measurement properties of the Montreal cognitive assessment in a population of people with cancer. Support Care Cancer. 2015;23(9):2779–2787.
   PubMed Web of Science ®Google Scholar
• Koski L, Xie H, Finch L. Measuring cognition in a geriatric outpatient clinic: Rasch analysis of the Montreal cognitive assessment. J Geriatr Psychiatry Neurol. 2009;22(3):151–160.
   PubMed Web of Science ®Google Scholar
• Yu J, Li J, Huang X. The Beijing version of the Montreal cognitive assessment as a brief screening tool for mild cognitive impairment: a community-based study. BMC Psychiatry. 2012;12:156.
   PubMed Web of Science ®Google Scholar
• Wen HB, Zhang ZX, Niu FS, et al. The application of Montreal cognitive assessment in urban Chinese residents of Beijing. Zhonghua Nei Ke Za Zhi. 2008;47(1):36–39.
   PubMedGoogle Scholar
• Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788–793.
   PubMed Web of Science ®Google Scholar
• Jansen CE, Cooper BA, Dodd MJ, et al. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19(10):1647–1656.
   PubMed Web of Science ®Google Scholar
• Wefel JS, Vidrine DJ, Veramonti TL, et al. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 2011;117(1):190–196.
   PubMed Web of Science ®Google Scholar
• Shiroishi MS, Gupta V, Bigjahan B, et al. Brain cortical structural differences between non-Central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. Proc SPIE Int Soc Opt Eng. 2017 Oct;10572:105720G.
   PubMedGoogle Scholar
• Dos Santos M, Lange M, Gervais R, et al. Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence. Support Care Cancer. 2019;27(9):3573–3581.
   PubMed Web of Science ®Google Scholar
• Bihorel S, Camenisch G, Lemaire M, et al. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (gleevec) across the mouse blood-brain barrier. J Neurochem. 2007;102(6):1749–1757.
   PubMed Web of Science ®Google Scholar
• Chen Y, Agarwal S, Shaik NM, et al. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther. 2009;330(3):956–963.
   PubMed Web of Science ®Google Scholar
• Pagan FL, Hebron ML, Wilmarth B, et al. Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with Parkinson's disease. Pharmacol Res Perspect. 2019;7(2):e00470.
   PubMed Web of Science ®Google Scholar
• Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models . Hum Mol Genet. 2013;22(16):3315–3328.
   PubMed Web of Science ®Google Scholar
• Lonskaya I, Hebron ML, Desforges NM, et al. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med (Berl). 2014;92(4):373–386.
   PubMed Web of Science ®Google Scholar
• Chan J, Shah P, Moguel-Cobos G. Nilotinib-Induced dystonia and cognitive deficits in a neurologically normal patient with chronic myeloid leukemia. Case Rep Neurol Med. 2019;2019:3679319.
   PubMed Web of Science ®Google Scholar
• Amieva H, Lafont S, Auriacombe S, et al. Analysis of error types in the trial making test evidences an inhibitory deficit in dementia of the alzheimer type. J Clin Exp Neuropsychol. 1998;20(2):280–285.
   PubMed Web of Science ®Google Scholar
• Hogervorst E, Combrinck M, Lapuerta P, et al. The Hopkins verbal learning test and screening for dementia. Dement Geriatr Cogn Disord. 2002;13(1):13–20.
   PubMed Web of Science ®Google Scholar
• Vannorsdall TD. Cognitive changes related to cancer therapy. Med Clin North Am. 2017;101(6):1115–1134.
   PubMed Web of Science ®Google Scholar
• John A, Patel U, Rusted J, et al. Affective problems and decline in cognitive state in older adults: a systematic review and meta-analysis. Psychol Med. 2019;49(3):353–365. Feb
   PubMed Web of Science ®Google Scholar